Security key
74065P101
Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share (PRLD)
CUSIP: 74065P101
Q4 2022 13F Holders as of 31 Dec 2022
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Total 13F shares
- 31,178,634
- Total 13F value
- $188,300,136
- Share change
- -667,401
- SEC-reported price per share
- $6.04
- Number of holders
- 59
- Value change
- -$4,385,760
- Number of buys
- 25
- Number of sells
- 27
- Shares outstanding
- 64,968,808
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2022
Institutions
59
Top holders
10
PRLD full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q1 2023
Previous quarter: Q3 2022
Prelude Therapeutics Inc SEC filings
Prelude Therapeutics Inc company facts
Broader feeds
Reporting periods
Holder history for CUSIP 74065P101
Recent filing periods:
Ownership snapshot
Top reported holders of PRLD - Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BAKER BROS. ADVISORS LP
Disclosed value leader
BAKER BROS. ADVISORS LP
Comparable rows
15/15
Latest evidence
30 Sep 2022
13F
Lead comparable stake: 16%
Showing 1-6 of 15 holder rows.
Quick read
BAKER BROS. ADVISORS LP leads the comparable SEC ownership view at 16%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BAKER BROS. ADVISORS LP's linked filing trail.
Comparable ownership
Top 5
BAKER BROS. ADVISORS LP
16%
ORBIMED ADVISORS LLC
15%
FMR LLC
7.1%
UBS AM, a distinct business unit ...
3.7%
VANGUARD GROUP INC
1.4%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP |
13F
Company
|
16%
|
$66,918,000
10,123,824 shares
|
— | 30 Sep 2022 |
| ORBIMED ADVISORS LLC |
13F
Company
|
15%
|
$66,362,000
10,039,691 shares
|
— | 30 Sep 2022 |
| FMR LLC |
13F
Company
|
7.1%
|
$30,660,000
4,638,532 shares
|
— | 30 Sep 2022 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC |
13F
Company
|
3.7%
|
$15,881,153
2,402,595 shares
|
— | 30 Sep 2022 |
| VANGUARD GROUP INC |
13F
Company
|
1.4%
|
$5,943,000
899,045 shares
|
— | 30 Sep 2022 |
| HHLR ADVISORS, LTD. |
13F
Company
|
0.9%
|
$3,856,000
583,333 shares
|
— | 30 Sep 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2022
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
59
Shares
31,178,634
Rows available
59
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2022 vs Q3 2022 Across Filers
Q3 2022 holders
50
Q4 2022 holders
59
Holder diff
9
| Investor | Q3 2022 Shares | Q4 2022 Shares | Share Diff | Share Chg % | Q3 2022 value | Q4 2022 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend